| Literature DB >> 32425305 |
Anuruddha Abeygunasekera1, Saroj Jayasinghe2.
Abstract
SARS-CoV-2 virus has resulted in a devastating pandemic of COVID-19. Exploring compounds that could offer a breakthrough in treatment is the need of the hour. Re-positioning cheap, freely available and safe drugs is a priority. The paper proposes evidence for the potential use of diethylcarbamazine (DEC) in the treatment of COVID-19. DEC has inhibitory effects on arachidonic acid metabolism to prostaglandins, little known anti-viral effects on animal retroviruses and demonstrated anti-inflammatory actions in animal models of lung inflammation indicating the need to explore this hypothesis further. We believe this is the first time DEC is being proposed to treat COVID-19.Keywords: COVID-19; Corona; Diethyl carbamazine DEC; SARS-CoV-2
Year: 2020 PMID： 32425305 PMCID： PMC7232076 DOI： 10.1016/j.mehy.2020.109843
Source DB: PubMed Journal: Med Hypotheses ISSN： 0306-9877 Impact factor: 1.538